Jefferies raises Certara stock price target to $12 on software growth

Jefferies raised its price target for Certara (CERT) to $12.00, citing improved software growth and organic bookings acceleration. The stock has risen 95% in six months, exceeding the new target. Certara reported Q3 2026 revenue of $94.9 million, up 2.81% from estimates, with software sales increasing 11%. UBS also raised its target to $13.00, noting strong biopharma demand.

Original reporting
Published Nov 6, 2026, 3:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 3:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$CERT
Neutral
medium confidence
Mentioned
$CERT
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CERTNeutralMed
01

Why it matters

Analyst upgrades provide fresh guidance but limited upside as the market price exceeds the new target.

02

Market read

The article offers a new analyst price target for Certara, which may influence short‑term trading but has modest broader market impact.

03

What to watch

Upcoming earnings or guidance could override the analyst's price target impact.

Relevance 6/10Novelty 6/10Timing: today

Background

Jefferies and UBS both raised price targets for Certara, citing accelerating software bookings and revenue growth.

Company-level read

Ticker impact

$CERTNeutralMedium confidence
Context

Jefferies raised its price target on Certara to $12 from $7.45 and maintained a Hold rating, marking a fresh analyst upgrade.

Expected impact

modest downside pressure as traders may book gains after the upgrade.

Evidence & confidence

Target raise is new information, but the market price already exceeds the level, limiting upside.

Market effects

The upgrade may lift sentiment toward the biotech software sector, but impact is limited.

U.S. market focus; no broader regional effect.

Low; relevance confined to Certara and its niche.

Counterpoint

With the stock already above the new target, the upgrade could be a false signal and trigger a pullback.

Key entities

  • Certara Inc.

    Provider of drug development software and services.

  • Jefferies

    Investment bank that raised the price target.

Related articles

$CERTMedAI 8/10

An Idle Mill and Old Open Pits Draw a New Plan in Southern Argentina

Cerrado Gold Inc. (TSX.V: CERT) (OTCQX: CRDOF) acquired a past-producing mine in Argentina for $20M, aiming to restart operations by 2027. The mine previously produced 1.4M gold equivalent ounces, with peak output of 137,500 ounces in 2011. The company plans a $40,000m drill program for a resource estimate, funded by its existing Santa Cruz operation.

$CERTHigh

Certara Software Revenue Jumps 11% as Services Decline

Certara Inc. (CERT) reported Q3 2026 software revenue growth of 11% to $48.8M, while services revenue declined 2% to $46.1M. Total revenue rose 4% to $94.9M, and net loss narrowed to $3.6M. Adjusted EBITDA increased 6% to $30.2M. The company maintained its full-year revenue growth forecast of 2-3% and updated its adjusted earnings outlook to 31-34 cents per share.

$CERTMed

Why Did Certara (CERT) Shares Climb After Its Latest Update?

Certara (CERT) reported Q3 2026 revenue of $94.9M, up from $90.89M a year earlier, with net income of $5.59M. However, nine-month revenue of $282.26M showed a net loss of $58.44M. Shares rose 9.83% in one day and 35.94% in 30 days, with a year-to-date return of 39.36%. The company's fair value is estimated at $8.71, suggesting a 40% overvaluation. Certara's AI-driven platforms and acquisitions aim to boost revenue and margins.

$CERTMed

Certara Inc (CERT) Q3 2026 Earnings Call Highlights: Software Growth Accelerates as Margins Expand

Certara Inc (CERT) reported Q3 2026 earnings with software revenue growth of 11% but services revenue declined 2% YoY to $46.1M. Full-year 2026 revenue growth guidance was narrowed to 2%-3%. CEO Jon Resnick highlighted cost savings exceeding $12M and strong software demand across customer tiers. The company is transitioning to a cloud-based model and investing in AI initiatives, expecting growth in 2027. GAAP net loss was $3.6M, and adjusted EPS remained flat at $0.09 YoY.

$CERTMed

Certara, Inc. Q3 2026 Earnings Call Summary

Certara reported 11% organic software revenue growth in Q3 2026, its first double-digit increase in two years. The company divested its Regulatory and Medical Writing business to focus on high-growth areas and reorganized operations. Management expects 2%-3% full-year revenue growth, with software outperforming services. AI capabilities and APAC market expansion are seen as growth drivers for 2027.